{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:55:18Z","timestamp":1792821318226,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,7,27]]},"DOI":"10.1038\/s41416-025-03025-1","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T14:08:58Z","timestamp":1746540538000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-4516","authenticated-orcid":false,"given":"Thomas F.","family":"Stoop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. H. Andrew","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7315-0830","authenticated-orcid":false,"given":"Atsushi","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-6323","authenticated-orcid":false,"given":"Mahsoem","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel M.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H.","family":"Al-Musawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Saiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Sauvanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar A.","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braden N.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyre","family":"Kleive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Sereni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Kazemier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Belfiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6947-9035","authenticated-orcid":false,"given":"Jacob L.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Dembinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitaka","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut J.","family":"Labori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motokazu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Gotohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Chatzizacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safi","family":"Dokmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Rodriguez Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Burgdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohei","family":"Satoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-9627","authenticated-orcid":false,"given":"Toru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Ushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vismaya","family":"Bachu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-023X","authenticated-orcid":false,"given":"Yu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Aslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Schulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9149-2247","authenticated-orcid":false,"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Del Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the International Consortium on Pancreatic Cancer Surgery and Oncology (ICON)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob L.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Del Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris V.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupaly","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier R.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland F.","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"3025_CR1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1200\/JCO.23.01311","volume":"42","author":"EN Dekker","year":"2024","unstructured":"Dekker EN, van Dam JL, Janssen QP, Besselink MG, DeSilva A, Doppenberg D, et al. Improved clinical staging system for localized pancreatic cancer using the ABC factors: a TAPS Consortium Study. J Clin Oncol. 2024;42:1357\u201367. https:\/\/doi.org\/10.1200\/JCO.23.01311.","journal-title":"J Clin Oncol"},{"key":"3025_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/jhbp.1049","volume":"29","author":"A Oba","year":"2022","unstructured":"Oba A, Del Chiaro M, Satoi S, Kim SW, Takahashi H, Yu J, et al. New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci. 2022;29:725\u201331. https:\/\/doi.org\/10.1002\/jhbp.1049.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"3025_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","volume":"21","author":"TF Stoop","year":"2024","unstructured":"Stoop TF, Theijse RT, Seelen LWF, Groot Koerkamp B, van Eijck CHJ, Wolfgang CL, et al. Preoperative chemotherapy, radiotherapy, and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:101\u201324. https:\/\/doi.org\/10.1038\/s41575-023-00856-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3025_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:987\u20131002. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.009.","journal-title":"Ann Oncol"},{"key":"3025_CR5","unstructured":"Tempero MA, Malafa MP, Benson AB, Cardin DB, Chiorean EG, Christensen JA, et al. Pancreatic Adenocarcinoma, Version 2.2024, NCCN clinical practice guidelines in oncology. National Comprehensive Cancer Network; 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455."},{"key":"3025_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/bjs\/znac354","volume":"110","author":"ZJ Brown","year":"2022","unstructured":"Brown ZJ, Heh V, Labiner HE, Brock GN, Ejaz A, Dillhoff M, et al. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Br J Surg. 2022;110:34\u201342. https:\/\/doi.org\/10.1093\/bjs\/znac354.","journal-title":"Br J Surg"},{"key":"3025_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","volume":"181","author":"M Ozaka","year":"2022","unstructured":"Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2022;181:135\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.014.","journal-title":"Eur J Cancer"},{"key":"3025_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","volume":"275","author":"J Yamaguchi","year":"2022","unstructured":"Yamaguchi J, Yokoyama Y, Fujii T, Yamada S, Takami H, Kawashima H, et al. Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg. 2022;275:1043\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000005430.","journal-title":"Ann Surg"},{"key":"3025_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99647-5","volume":"11","author":"YS Lee","year":"2021","unstructured":"Lee YS, Lee JC, Kim JH, Kim J, Hwang JH. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. Sci Rep. 2021;11:20152. https:\/\/doi.org\/10.1038\/s41598-021-99647-5.","journal-title":"Sci Rep"},{"key":"3025_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Shaalan Beg M, Wang-Gillam A, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7:421\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7328.","journal-title":"JAMA Oncol"},{"key":"3025_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"3025_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.6004\/jnccn.2019.0014","volume":"17","author":"MA Tempero","year":"2019","unstructured":"Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, et al. Pancreatic adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019;17:202\u201310. https:\/\/doi.org\/10.6004\/jnccn.2019.0014.","journal-title":"J Natl Compr Canc Netw"},{"key":"3025_CR13","doi-asserted-by":"crossref","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Chichester, West Sussex: Wiley-Blackwell; 2010.","DOI":"10.1002\/9780471420194.tnmc26"},{"key":"3025_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"3025_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.surg.2014.02.009","volume":"156","author":"W Hartwig","year":"2014","unstructured":"Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery. 2014;156:1\u201314. https:\/\/doi.org\/10.1016\/j.surg.2014.02.009.","journal-title":"Surgery"},{"key":"3025_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg"},{"key":"3025_CR17","unstructured":"Campbell F, Foulis A, Verbeke C. Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. London: The Royal College of Pathologists; 2010."},{"key":"3025_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.surg.2017.05.003","volume":"162","author":"HS Tran Cao","year":"2017","unstructured":"Tran Cao HS, Zhang Q, Sada YH, Silberfein EJ, Hsu C, Van Buren G 2nd, et al. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery. 2017;162:557\u201367. https:\/\/doi.org\/10.1016\/j.surg.2017.05.003.","journal-title":"Surgery"},{"key":"3025_CR19","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175\u201397. https:\/\/doi.org\/10.1002\/sim.1203.","journal-title":"Stat Med"},{"key":"3025_CR20","unstructured":"Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model. Texas: Stata Press; 2011."},{"key":"3025_CR21","unstructured":"Lambert PC. STPM3: Stata module to fit flexible parametric survival models. Chestnut Hill: Boston College Department of Economics; 2023."},{"key":"3025_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.pan.2020.06.012","volume":"20","author":"M Weniger","year":"2020","unstructured":"Weniger M, Moir J, Damm M, Maggino L, Kordes M, Rosendahl J, et al. Respect\u2014a multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Pancreatology. 2020;20:1131\u20138. https:\/\/doi.org\/10.1016\/j.pan.2020.06.012.","journal-title":"Pancreatology"},{"key":"3025_CR23","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1245\/s10434-018-6512-8","volume":"25","author":"M Dhir","year":"2018","unstructured":"Dhir M, Zenati MS, Hamad A, Singhi AD, Bahary N, Hogg ME, et al. FOLFIRINOX versus gemcitabine\/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma. Ann Surg Oncol. 2018;25:1896\u2013903. https:\/\/doi.org\/10.1245\/s10434-018-6512-8.","journal-title":"Ann Surg Oncol"},{"key":"3025_CR24","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1002\/cam4.3075","volume":"9","author":"AR Wolfe","year":"2020","unstructured":"Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, et al. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med. 2020;9:4711\u201323. https:\/\/doi.org\/10.1002\/cam4.3075.","journal-title":"Cancer Med"},{"key":"3025_CR25","first-page":"75","volume":"19","author":"BC Chapman","year":"2018","unstructured":"Chapman BC, Gleisner A, Rigg D, Messersmith W, Paniccia A, Meguid C, et al. Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine abraxane in patients with pancreatic adenocarcinoma. JOP. 2018;19:75\u201385.","journal-title":"JOP"},{"key":"3025_CR26","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.hpb.2019.03.139","volume":"21","author":"MM Gage","year":"2019","unstructured":"Gage MM, Wang P, Overton H, Sham JG, Javed AA, Burkhart RA, et al. Folfirinox is associated with a long-term survival benefit compared to gemcitabine-abraxane for neoadjuvant therapy before pancreatic cancer surgery. HPB. 2019;21:S84. https:\/\/doi.org\/10.1016\/j.hpb.2019.03.139.","journal-title":"HPB"},{"key":"3025_CR27","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.21037\/gs-21-16","volume":"10","author":"R Tang","year":"2021","unstructured":"Tang R, Meng Q, Wang W, Liang C, Hua J, Xu J, et al. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy for localized pancreatic cancer: a systematic review and meta-analysis. Gland Surg. 2021;10:1564\u201375. https:\/\/doi.org\/10.21037\/gs-21-16.","journal-title":"Gland Surg"},{"key":"3025_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/SLA.0000000000003468","volume":"270","author":"FI Macedo","year":"2019","unstructured":"Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine\/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg. 2019;270:400\u201313. https:\/\/doi.org\/10.1097\/SLA.0000000000003468.","journal-title":"Ann Surg"},{"key":"3025_CR29","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jamasurg.2020.2286","volume":"155","author":"G Perri","year":"2020","unstructured":"Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, et al. Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. JAMA Surg. 2020;155:832\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2020.2286.","journal-title":"JAMA Surg"},{"key":"3025_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/cancers11070981","volume":"11","author":"F Napolitano","year":"2019","unstructured":"Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, et al. Neoadjuvant treatment in locally advanced pancreatic cancer (LAPC) patients with FOLFIRINOX or gemcitabine nabpaclitaxel: a single-center experience and a literature review. Cancers. 2019;11:981. https:\/\/doi.org\/10.3390\/cancers11070981.","journal-title":"Cancers"},{"key":"3025_CR31","doi-asserted-by":"publisher","first-page":"e2417625","DOI":"10.1001\/jamanetworkopen.2024.17625","volume":"7","author":"TF Stoop","year":"2024","unstructured":"Stoop TF, Oba A, Wu YHA, Beaty LE, Colborn KL, Janssen BV, et al. Pathological complete respons in patients with resected pancreatic adenocarcinoma after preoperative chemotherapy. JAMA Netw Open. 2024;7:e2417625. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.17625.","journal-title":"JAMA Netw Open"},{"key":"3025_CR32","doi-asserted-by":"publisher","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","volume":"28","author":"QP Janssen","year":"2021","unstructured":"Janssen QP, van Dam JL, Kivits IB, Besselink MG, Van Eijck CHJ, Homs MYV, et al. Added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2021;28:8297\u2013308. https:\/\/doi.org\/10.1245\/s10434-021-10276-8.","journal-title":"Ann Surg Oncol"},{"key":"3025_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8:1263\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2319.","journal-title":"JAMA Oncol"},{"key":"3025_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrae162","volume":"9","author":"S Augustinus","year":"2024","unstructured":"Augustinus S, Sijberden JP, Bieze M, Agarwal V, Aldrighetti LA, et al. Inter-rater variability for the American Society of Anesthesiologists classification in patients undergoing hepato-pancreato-biliary surgery (MILESTONE-2): international survey among surgeons and anaesthesiologists. BJS Open. 2024;9:zrae162. https:\/\/doi.org\/10.1093\/bjsopen\/zrae162.","journal-title":"BJS Open"},{"key":"3025_CR35","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"key":"3025_CR36","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1809775.","journal-title":"N Engl J Med"},{"key":"3025_CR37","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djz073","volume":"111","author":"QP Janssen","year":"2019","unstructured":"Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782\u201394. https:\/\/doi.org\/10.1093\/jnci\/djz073.","journal-title":"J Natl Cancer Inst"},{"key":"3025_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(16)00172-8.","journal-title":"Lancet Oncol"},{"key":"3025_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","volume":"6","author":"V Kunzmann","year":"2021","unstructured":"Kunzmann V, Siveke JT, Alg\u00fcl H, Goekkurt E, Siegler G, Martens U, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:128\u201338. https:\/\/doi.org\/10.1016\/S2468-1253(20)30330-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3025_CR40","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"key":"3025_CR41","doi-asserted-by":"publisher","unstructured":"Dekker EN, Narayan RR, Ahmami MA, Meddouch A, Verkolf EMM, Gehrels AM, et al. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. Br J Surg. 2024;111. https:\/\/doi.org\/10.1093\/bjs\/znae244.","DOI":"10.1093\/bjs\/znae244"},{"key":"3025_CR42","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.21037\/jgo-20-426","volume":"12","author":"B Kinny-K\u00f6ster","year":"2021","unstructured":"Kinny-K\u00f6ster B, Habib J, Wolfgang CL, He J, Javed AA. Favorable tumor biology in locally advanced pancreatic cancer\u2014beyond CA19-9. J Gastrointest Oncol. 2021;12:2484\u201394. https:\/\/doi.org\/10.21037\/jgo-20-426.","journal-title":"J Gastrointest Oncol"},{"key":"3025_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","volume":"26","author":"NU Rashid","year":"2020","unstructured":"Rashid NU, Peng XL, Jin C, Moffitt RA, Volmar KE, Belt BA, et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for Tumor subtyping in pancreatic cancer. Clin Cancer Res. 2020;26:82\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1467.","journal-title":"Clin Cancer Res"},{"key":"3025_CR44","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-22-3089","volume":"29","author":"BL Ecker","year":"2023","unstructured":"Ecker BL, Tao AJ, Janssen QP, Walch HS, Court CM, Balachandran VP, et al. Genomic biomarkers associated with response to induction chemotherapy in patients with localized pancreatic ductal adenocarcinoma. Clin Cancer Res. 2023;29:1368\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3089.","journal-title":"Clin Cancer Res"},{"key":"3025_CR45","doi-asserted-by":"publisher","unstructured":"Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, et al. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev. 2019;801895: https:\/\/doi.org\/10.1016\/j.ctrv.2019.101895.","DOI":"10.1016\/j.ctrv.2019.101895"},{"key":"3025_CR46","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/SLA.0000000000002957","volume":"268","author":"S Tsai","year":"2018","unstructured":"Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, et al. A phase II clinical trial of molecular profiled neoadjuvant therapy for localized pancreatic ductal adenocarcinoma. Ann Surg. 2018;268:610\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000002957.","journal-title":"Ann Surg"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03025-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:04:26Z","timestamp":1752138266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03025-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7,27]]}},"alternative-id":["3025"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03025-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MDC has been awarded with an industry grant (Haemonetics, Inc) to conduct a multicenter study to evaluate the prognostic implications of TEG in pancreatic cancer. MDC is co-principal investigator of a Boston Scientific sponsored international multicenter study on the use of intraoperative pancreatoscopy of patients with IPMN. TFS, JWW, and MGB received two grants from Dutch Cancer Society (KWF) and Deltaplan Alvleesklierkanker for the Dutch PREOPANC-4 project on the multidisciplinary management of LAPC. TFS is granted by the Cultuurfonds (Jan de Ruijsscher\/Pia Huisman Fonds) and Cancer Center Amsterdam. AO has been awarded with a grant (Bayer Yakuhin, Ltd.) to conduct an observation study to investigate the clinical impact of EOB-MRI. SS discloses receipt of research funding from Nihon Servier, Boston Scientific, and Amino-up co.jp. JWW received research grants from Servier, Nordic, and MSD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study procedures were reviewed and approved by the Colorado Multiple Institutional Review Board (COMIRB) (protocol #19-2972) at the University of Colorado. The need for informed consent was waived because of the retrospective nature of this study. A previously created dataset was used to identify patients for this study [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}